Stock trading down to 1.10 on low volume. Panic sellers, don't understand this capital is necessary for growing the company. I do question the need for it now however, as they have the stock purchase agreement in place with Aspire Capital, that should have given them the legs to have extended this well into next year had they used it. Maybe they didn't like the terms of that agreement? Anyone here have insight?
You expect positive results in this instance, yet your earlier post I replied to "on a positive note" reads otherwise?
Schwab called me yesterday to try to interest me in loaning my shares for a 7% return. I declined to do so, as I oppose the whole paradigm of shorting biotech stocks, seems immoral to try to undermine companies seeking a cure for terrible disease. The shorts want more leverage on this name, do all we can to fight it, refuse to yield to their cause.
Four of my stocks were either flat or up, compared to 6 down, this was the highest percentage leader of my losers. O/T take a look at ATHX. The near term catalyst is May 5th ER call, I'll say no more.
And thank you for a comprehensive well written article. Love your handle here, reflects well on your expertise, now confirmed with the article. Keep up the good work, we appreciate it. I keep adding, twice this week, as low as 2.29 and again today at 2.36 after reading your article.
Sentiment: Strong Buy
That was it, of course, MM waited for a quiet day, caught me by surprise. There's an interesting post over on the Sage YMB, by a basher, can't say that his point may not have merit:
joe120055 • Mar 25, 2016 12:54 PM Flag
1users liked this postsusers disliked this posts2Reply
The Cambridge based VC firms have been running a profitable Ponzi scheme for years now. Sage is just one of the latest installments. By now, it is a well-oiled machine and goes something like this:
I found it interesting, if you do, go there and read the thread, too long to re-post here. As I type this, we are trading at 5.70 having briefly eclipsed 5.80 on the way back up from 5.55.
Call to Action for Participation in Clinical Trials is Topic of Symposium at Alzheimer's Disease International Conference 2016
Event Featuring Marc Wortmann of ADI and Professor Dr. Harald Hampel to be Streamed Live on the Web
PR Newswire Axovant Sciences Ltd.
April 19, 2016 7:30 AM
HAMILTON, Bermuda, April 19, 2016 /PRNewswire/ -- Axovant Sciences Ltd. (AXON) today announced it is sponsoring a symposium at the Alzheimer's Disease International Conference 2016: "Alzheimer's Community Call to Action: Developing New Treatments Through Clinical Trial Participation."
Here's what Harold had to say (he's an esteemed member of our scientific advisory board at Anavex):
"No new chemical entity has been approved for treatment of Alzheimer's disease in over a decade, but there are several potential treatments in the final stages of clinical development," said Dr. Hampel. "I look forward to sharing more information about the latest research trends, and the important role patients and caregivers play in contributing to this research."
"Too often, people with dementia and their caregivers may not be aware of clinical trial opportunities available to them, or the importance of participation," said Mr. Wortmann. "I look forward to sharing information on what Alzheimer's associations can do to help educate their members about these opportunities."
April 26th, stock down 3 cents to 1.30. It's clear April wasn't our month to break out of this very controlled price range. May should be better, good luck all longs.
Looking at my portfolio of 9 stocks, there is evidence everywhere of the short trade taking money out of the various market caps and our pockets. I have two stocks up, one flat, and 6 down. They are pulling even as little as two cents a day out of names like GALE. AVXL after a monster day two days ago, down .14. Will there ever be a day when we see these cockroaches fry and be squeezed hard? I get so tired of them wearing against these companies. Biotech must be their favorite sector due to high failure rate of trials and the dearth of news flow.
Overstated, not happening, sector is climbing back, IBB and XBI are in improving quadrant and won't be long before XLV is back in leading quadrant together with these ETF's mentioned. I hold 9 biotechs, worst one is down 3% today. If you hold SRPT, you are hurting today but the sector isn't getting slaughtered.
Are you always this negative, or didn't you notice the stock was up 12 cents AH? 91% of gaps fill, however, this is oversold now, not going to be oversold. Have a little perspective, we aren't going to get to your downside 3.37 target. Today was a higher low, a pronounced impulse higher low, how many stocks lose 24% in a day when an employee leaves, CEO is hired? We may trade around this level a few days, even go marginally lower, but recovery has already started as people get used to the changes.
I did just that today and added 1,600 shares at 2.29 15-20 minutes before the close. I was rewarded with a 6 cent equity in the closing minutes. After an intra-day reversal like today, this may lead to continuation tomorrow, for a resumption of the uptrend leading into next week's conference call. GLAL.
Looks like the curious run of the 3,824 'share buys' has come to an end, sadly. I also reviewed trades during the last 10 minutes but didn't find a lot of 3,824 shares. We likely won't ever know what this was all about, but the theories advanced here as to it being a coded message kept the entertainment value running for two weeks. 10 days = 38,240 shares, a decent position if I may add. GLAL.
Bought more today at 2.29, in last half hour, then it rallied into the close. Thank your team for driving the price down so us buyers could sweep in to accumulate on the lows of the last week. Now, get lost loser.
Great point Ranger, like your thinking there. Has anyone noticed we have a pennant formation since the 15th on the hourly chart? Very bullish formation in my view. While this is a form of consolidation of our gains, it portends a breakout to the upside more often than not. What's it going to take, random trading on a good biotech day or news? Either way, that we are trading up today is a good sign in an otherwise sideways to down day.
Yes, yes, no, yes, that's my 2 cents. Anemic volume, no news, low morale matches trending lower price point, when action elsewhere spells lost opportunity.
You misrepresent what was covered in the video, and where are longs saying 100-200%? Lies.